natgillin/translations-raw huggingface dataset:
It is therefore expected that inhibitors of erbB type receptor tyrosine kinases will be useful in the treatment of these and other non-malignant disorders of excessive cellular proliferation. 
Stoga se može očekivati da bi inhibitori erbB tipa receptorskih kinaza mogli biti korisni u liječenju ovih i drugih ne-malignih poremećaja prekomjerne stanične proliferacije.
For the treatment of anal incontinence, the hydrogel is typically injected into the colon or rectum (canalis analis) specifically under the submucosal membrane of the colon or rectum. 
Za liječenje analne inkontinencije, hidrogel se tipično injektira u debelo crijevo ili u rektum (canalis analis) naročito ispod submukozne membrane debelog crijeva ili rektuma.
one of the groups R1 and R2 is the group R20-NH- and the other of the groups R1 and R2 is the group (R30)(R31)N-; 
jedna od skupina R1 i R2 je skupina R20-NH- i druga od skupina R1 i R2 je skupina (R30)(R31)N-;
The method according to claim 7 or 8, wherein: the receiving, by the data sending end, the encoded information sent by the terminal specifically comprises: receiving, by the data sending end, the encoded information sent by the terminal through a physical uplink control channel PUCCH or a physical uplink shared channel PUSCH. 
Postupak prema zahtjevu 5, naznačen time da: prijem, od strane koja šalje podatke, kodiranih informacija poslanih pomoću terminala koji specifično sadrži: prijem, od strane koja šalje podatke, kodirane informacije poslane pomoću terminala kroz kontrolni kanal fizičke uzlazne veze, PUCCH ili dijeljeni kanal fizičke uzlazne veze, PUSCH.
The edging strip as claimed in claim 1, characterized in that hardness and melting point of the melt layer is about the same as that of other layers of the edging strip that are present, and the edging strip has a constant melting point. 
Rubna traka prema jednom od prethodnih zahtjeva, naznačena time, što sloj taljevine ima usporedivu tvrdoću i temperaturu taljenja u odnosu na druge slojeve tako da cjelokupna rubna traka ima konstantnu temperaturu taljenja.
The recombinant adenosine deaminase of claim 2 that is translated from a DNA molecule according to SEQ ID NO: 2 or SEQ ID NO: 4. 
Rekombinantna adenozin deaminaza u skladu s patentnim zahtjevom 2, naznačena time, da je prevedena od DNA molekule u skladu sa SEQ ID NO: 2 ili SEQ ID NO: 4.
Use of a cocktail of CRISPR-escape phage mutants obtainable by the process of claim 1 as a biocontrol agent against a bacterial population, and wherein the bacterial population is selected from Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, Listeria, Agrobacterium, Staphylococcus,Enterococcus, Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia,Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Rickettsia, Shewanella,Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, Streptococcus, and Oenococcus. 
Postupak prema zahtjevu 1, naznačen time da je navedeni matični bakterijski soj odabran od bakterija Escherichia, Shigella, Salmonella, Erwinia, Yersinia, Bacillus, Vibrio, Legionella, Pseudomonas, Neisseria, Bordetella, Helicobacter, = Listeria, - Agrobacterium, = Staphylococcus, = Streptococcus, = Enterococcus, = Clostridium, Corynebacterium, Mycobacterium, Treponema, Borrelia, Francisella, Brucella, Campylobacter, Klebsiella, Frankia, Bartonella, Ricketisia, Shewanella, Serratia, Enterobacter, Proteus, Providencia, Brochothrix, Bifidobacterium, Brevibacterium, Propionibacterium, Lactococcus, Lactobacillus, Pediococcus, Leuconostoc, te Oenococcus.
The pharmaceutical preparations of the invention are moreover particularly suitable for administration to groups of patients who are suffering from the abovementioned diseases and have problems in taking pharmaceutical preparations to be administered orally, such as, for example, bedridden patients, patients in intensive medical care, patients with swallowing difficulties and children. 
Farmaceutski pripravci izuma su nadalje posebno prikladni za primjenu skupinama pacijenata koji pate od gore navedenih oboljenja i imaju problema s oralnim uzimanjem pripravaka, poput, na primjer, pacijenata vezanih uz krevet, pacijenata na intenzivnoj medicinskoj skrbi, pacijenata koji imaju problem s gutanjem i djece. HR P20080640 T3
A method for increasing the pH of an aqueous suspension containing from 25 to 62 vol. % of at least one calcium carbonate-comprising material and having a pH in the range of between 8.5 and 11, characterized in that the method involves the step of adding 2-((1-methylpropyl)amino)ethanol to the suspension in an amount, so that the pH of the suspension is increased by at least 0.3 pH units and, at the same time, the suspension conductivity change is not more than 100 µS/cm per pH unit, and characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, per liter of the aqueous phase of said suspension. 
HR P20130607 T1 PATENTNI ZAHTJEVI U poraba 2-((1-metilpropil)aminojetanola kao aditiva u vodenoj otopini, sadrži 25 do 62 vol.% na temelju ukupnog volumena otopine, barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 i 11, za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 uS/cm po jedinici pH, karakterizirana na način da je navedeni 2-((1-metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 1500 mg, po litri vodene faze navedene otopine.
The stable aqueous aldehyde solution according to claim 1 wherein the aldehyde is selected from the group consisting of: glutaraldehyde and ethane dialdehyde; ethane dialdehyde and chloraldehyde trihydrate; acetaldehyde and Glyoxal™; paraformaldehyde and glutaraldehyde, glutaraldehyde and succinaldehyde and ethane dialdehyde and succinaldehyde. 
Stabilna vodena otopina aldehida u skladu s patentnim zahtjevom 1 pri čemu je aldehid odabran između jednog od sljedećih: glutaraldehida i glioksala; glioksal kloraldehida trihidrata; acetaldehida i glioksal paraformaldehida i glutaraldehida; glutaraldehida i sukcinaldehida; i glioksala i sukcinaldehida.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: Oxycodone hydrochloride: 10.0 mg/tablet Lactose (spray-dried): 69.25 mg/tablet 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja sadrži 10 mg oksikodon hidroklorida kada je ispitivan u komparativnoj kliničkoj studiji je sa referentnom tabletom koja sadrži 10 mg oksikodon hidroklorida u matričnoj formulaciji koja sadrži: a) "Oksikodon hidroklorid: 10.0 mg/tableta b) Laktozu (osušena raspršivanjem): 69.25 mg/tableta c) Povidon: 5.0 mg/tableta d) Eudragit* RS 30D (krutina): 10.0 mg/tableta
A method for inhibiting anti-apoptotic Bc1-2 protein function in a cell comprising contacting a cell comprising anti-apoptotic Bc1-2 protein with the compound or therapeutically acceptable salt of any one of claims 1 and 2 . 
Farmaceutski pripravak, naznačen time, da sadržava inertni nosač 1 terapeutski učinkovitu količinu spoja ili terapeutski prihvatljivu sol u skladu s patentnim zahtjevom 1 ili 2.
The system according to claim 1, wherein the hydrogel is cross-linked. 
(b) hidrogel je unakrsno povezan; i/ili
The formulation in the form of a film, cutaneous stick, lip balm, or lipstick according to claim 21 comprising, as active ingredients, plant extracts, and optionally comprising dyes, fragrances, and/or excipients. 
Formulacija u obliku filma, štapića za kožu, balzama za usne ili ruža u skladu s patentnim zahtjevima 21 ili 22, naznačena time, da kao aktivne sastojke sadržava biljne ekstrakte i po izboru sadržava boje, mirise 1 / ili ekscipijente.
% and an ash content of less than 0.1 wt. 
% i sadržaj pepela od manje od 0,1 wt.
Dorzolamide hydrochloride was first disclosed in the European patent EP 296879. 
EP 07728156.6 Datum podnošenja europske prijave patenta:
Cytotoxicity in HL-60 cells. 
Citotoksicitet u HL-60 stanicama.
The composition of any preceding claim, wherein the composition is for use in a patient with elevated IL-17 levels or Thl7 cells, and/or wherein the composition is for use in a method of reducing IL-17 production or reducing Thl7 cell differentiation in the treatment or prevention of the inflammatory disease. 
Sastav za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je sastav za upotrebu u postupku smanjenja proizvodnje IL-17 ili smanjenja diferencijacije Th17 stanica u liječenju ili prevenciji upalne ili autoimune bolesti.
BCH-decoding the LDPC-decoded Layer 1 signaling data and the de-punctured LDPC parity bit, characterized in that the Layer 1 signaling data includes a notch start information field indicating a start position of an associated notch band, wherein the number of bits used for the notch start information field varies with a guard interval value. 
BCH dekodiranje LDPC-dekodiranog signalnog podatka razine 1, karakterizirano na način da signalni podatak razine 1 uključuje polje s informacijom početka obilježja koje ukazuje na početni položaj pridružene širine obilježja, pri čemu broj bitova korišten za polje s informacijom početka obilježja varira s vrijednosti intervala čuvara,
monitoring electrical conductivity of an aqueous cooling medium in at least one location. The method of claim 1, wherein the electrical conductivity of the aqueous cooling medium is monitored separately in each cooling circuit. 
Metoda sukladno patentnom zahtjevu 1, naznačena time što u okviru iste se električna vodljivost rashladnog medija, koji za rashlađivanje koristi vodu, nadzire zasebno u svakom rashladnom krugu.
Test Article Carrier and Control Articles 
A. Nosač test spojeva i kontrolni spojevi
The method of embodiment 27, wherein the Shield-1 is present at a concentration of at least 0.5 µM. 
Postupak prema patentnom zahtjevu 16, naznačen time što Shield-1 je prisutan u koncentraciji od najmanje 0.5 uM.
The shampoo or conditioner of any of claims 62-67, further comprising one or more cosmetically acceptable excipients, wherein the one or more excipients are selected from the group consisting of water, surfactants, vitamins, natural extracts, preservatives, chelating agents, perfumes, preservatives, antioxidants, chelating agents, hair coloring agents, proteins, amino acids, humectants, fragrances, emollients, penetrants, thickeners, viscosity modifiers, hair fixatives, film formers, emulsifiers, opacifying agents, propellants, liquid vehicles, carriers, salts, pH adjusting agents, neutralizing agents, buffers, hair conditioning agents, anti-static agents, anti-frizz agents, anti-dandruff agents, and combinations thereof. 
Å ampon ili regenerator prema bilo kojem od zahtjeva 62-67, naznačen time da nadalje sadrži jedno ili više kozmetički prihvatljivih pomoćnih sredstava, pri čemu je jedno ili više pomoćnih sredstava odabrano iz skupine koju čine voda, površinski aktivno sredstvo, vitamini, prirodni ekstrakti, konzervansi, sredstva za kelatiranje, parfemi, sredstva za održavanje, antioksidansi, kelatirajuća sredstva, sredstvo za bojenje kose, proteini, amino kiseline, sredstva za vlaženje, mirisi, emolijenti, sredstva za prodiranje, sredstva za zgušnjavanje, modifikatori viskoziteta, učvršćivači kose, sredstva koja tvore film, emulgatori, sredstva za zamućivanje, propelanti, tekuća sredstva, nosači, soli, sredstva za podešavanje pH, sredstva za neutralizaciju, puferi, sredstva za regeneraciju kose, antistatička sredstva, sredstva protiv kovrčanja, sredstva protiv prhuti i njihove kombinacije.
A method for monitoring minimal residual glaucoma, optic neuritis, or lattice dystrophy in a subject following treatment with the pharmaceutical composition of claim 1, wherein said method comprises: bringing a sample of the subject suspected to contain the amyloid protein into contact with a monoclonal antibody comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 9; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 10; a light chain CDR3 having the amino acid sequence of SEQ ID NO: 11; a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 12; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 13; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 14, or a functional part thereof, which antibody binds an epitope of the amyloid protein; 
Postupak praćenja minimalnog rezidualnog glaukoma, optičkog neuritisa ili retikularne distrofije kod subjekta nakon liječenja farmaceutskim pripravkom u skladu s patentnim zahtjevom 1, naznačen time što se navedeni postupak sastoji u: (a) stavljanju uzorka iz subjekta za koji se sumnja da sadrži amiloidni protein u kontakt s monoklonskim protutijelom koje sadrži CDRI lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 13; i CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 14, ili njegovim funkcionalnim dijelom, gdje se navedeno protutijelo veže na epitop u amiloidnom proteinu;
The subject of the invention is application of natural mineral water with special qualities in prophylaxis, hygiene and treatment of teeth and paradontium. 
Prirodna mineralna voda prema zahtjevu 1 naznačena time da je za upotrebu kod profilakse i tretmana paradontopatije.
The pharmaceutical composition for use according to claim 1 or 2, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3f-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 50 ng/ml do 250 ng/ml.
The extended release dosage form of claim 12, wherein the opioid analgesic is oxycodone hydrochloride and the dosage form comprises from about 5 mg to about 500 mg of oxycodone hydrochloride, preferably 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, or 80 mg, 90 mg, 120 mg or 160 mg of oxycodone hydrochloride. 
Oblik davanja s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 12, naznačen time da oblik davanja sadrži 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 45 mg, 60 mg, 80 mg, 90 mg, 120 mg ili 160 mg oksikodon hidroklorida.
m is an integer ranging from 0 to 3; 
m je cijeli broj od 0 do 3;
The 2'R isomer of TPI 285 is illustrated, for example, with respect to generalized Formula A in Figure 1 wherein R1 is a tert-butoxyl group, R2 is an isobutyl group and R7 is acetyl. 
Izomer 2'R od TPI 285 je prikazan, na primjer, u odnosu na opću formulu A na slici 1, gdje je R, tert-butoksil skupina, R, je izobutil skupina i R; je acetil.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least five CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1, comprising heavy and light chain CDR sequence combinations (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) selected from the group consisting of SEQ ID NO: 3/4/5/8/9/10 and 53/54/55/58/59/60, or which competes for binding to at least five CC chemokines selected from CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, and CCL23/MPIF-1, with an antibody or antigen binding fragment comprising heavy and light chain CDR sequence combinations selected from the group consisting of SEQ ID NO: 3/4/5/8/9/10 and 53/54/55/58/59/60. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje pet CC kemokina odabranih iz skupine koja se sastoji od CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, i koji se ne veže na CCL2/MCP-1, koji sadrži kombinacije CDR nizova teških i lakih lanaca (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) odabranih iz skupine koja se sastoji od SEQ ID NO: 3/4/5/8/9/10 i 53/54/55/58/59/60, ili koji se natječe za vezanje na najmanje pet CC kemokina odabranih iz CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, CCL15/HCC-2, i CCL23/MPIF-1, s antitijelima, ili fragmentom koji veže antigen koji sadrži kombinacije CDR slijeda teškog i lakog lanca odabranih iz skupine koja se sastoji od SEQ ID NO: 3/4/5/8/9/10 i 53/54/55/58/59/60.
The method of claim 1 wherein the crosslinked amine polymer comprises the residue of an amine corresponding to Formula 1a and the crosslinked amine polymer is prepared by radical polymerization of an amine corresponding to Formula 1a: 
Farmaceutski pripravak za upotrebu prema bilo kojem od zahtjeva 1-3, naznačen time da umreženi aminski polimer sadrži ostatak amina koji odgovara formuli 1a i umreženi aminski polimer je dobiven radikalnom polimerizacijom amina koji odgovara formuli 1a:
The composition of any one of claims 1-7, further comprising embryonic stem cells, adult stem cells, induced pluripotent stem cells, epithelial cells, exocrine or endocrine cells, myoblasts, fibroblasts, osteoblasts, chondroblasts, stromal cells, hepatocytes, islet cells, neuroblasts keratinocytes, osteoclasts, osteocytes, cardiac cells, chondrocytes, endothelial cells, or muscle cells, or any combination thereof. 
Smjesa prema bilo kojem od zahtjeva 1-7, koja nadalje sadrži embrijske matične stanice, odrasle matične stanice, inducirane pluripotentne matične stanice, epitelne stanice, egzokrine 1li endokrine stanice, mioblaste, fibroblaste, osteoblaste, hondroblaste, stromalne stanice, hepatocite, stanice otočiće, neuroblaste, keratinocite, osteoklaste, osteocite, srčane stanice, hondrocite, endotelne stanice ili mišićne stanice ili bilo koju njihovu kombinaciju.
parts of the resin thus obtained were dissolved in 67 parts of water. 
HR P940799 B1 33 dijela tako dobijene smole otopimo u 67 dijelova vode.
In a particularly preferred embodiment the present invention relates to microcapsules, wherein the liver cells are selected from the group consisting of hepatic precursor cells, hepatic stem cells, hepatoblasts, hepatocytes and endothelial cells. 
Mikrokapsule prema zahtjevu 1, naznačene time da su stanice jetre odabrane iz skupine koja sadrži prekursorske stanice jetre, matične stanice jetre, hepatoblaste, endotelne stanice 1 hepatocite.
the chromatography method is a hydrophobic interaction chromatography method, and the reagent functionalises the chromatography medium with a propyl, butyl, phenyl, or octyl group; or 
metoda kromatografije jeste metoda hidrofobne interakcije, a reagens funkcionalizira sredstvo za kromatografiju propilnom, butilnom, fenilnom ili oktilnom grupom; ili
The pharmaceutical composition according to claim 3 or claim 4, wherein said Omega-3 fatty acid ester is an ethyl ester derivative of said Omega-3 fatty acid ester. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 3 ili patentnim zahtjevom 4, naznačen time što je navedeni ester omega-3 masne kiseline etilni esterski derivat navedenog estera omega-3 masne kiseline.
Use according to claim 35, wherein said inflammatory conditions and immune disorders are selected from the group consisting of inflammatory conditions or immune disorders of the lungs, joints, eyes, bowel, skin, and heart. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se navedena upalna stanja i imunosne poremećaje bira iz skupine koju čine upalna stanja ili imunosni poremećaji pluća, zglobova, očiju, crijeva, kože i srca.
Glucose isomerase for use according to claim 1 or claim 2 wherein the glucose isomerase is contained in a pharmaceutical composition. 
Glukoza izomeraze za uporabu u skladu s bilo kojim zahtjevom 1 do 7, naznačena time, što glukoza izomeraze je sadržana u farmaceutskom sastavu.
Preventive and curative effect on atherogenesis in apo E-deficient mouse 
Preventivan i kurativan učinak na aterogenezu u apo E-deficijentnim miševima
A pharmaceutical composition comprising the vector of any one of items 94 to 98 or the adenovirus of item 99 or 100 and a pharmaceutically acceptable carrier, wherein the composition does not contain another type of adenovirus. 
Farmaceutski sastav sadržeći (1) - vektor iz zahtjeva 2; 1 (ii) farmaceutski prihvatljiv nosač naznačeno time da sastav ne sadrži drugu vrstu adenovirusa.
the reaction of a compound of formula (A) in the presence of NHR3R4, an amide bond forming coupling agent and a base; or the reaction of a compound of formula (B) with a compound of formula R4-X; 
(a) reakcija spoja formule (A) u prisutnosti NHR>R", amidne veze koja stvara spoj agensa i baze; ili | (b) reakcija spoja formule (B)
Preferably, the packaging comprises guiding members for providing that the step of closing is done in a controlled manner avoiding the two sides of the packaging from displacing in relation to each other. 
Poželjno je da pakiranje sadržava članove za vođenje koji osiguravaju da se korak zatvaranja izvede na kontroliran način, sprečavajući da se dvije strane pakiranja pomaknu jedna u odnosu na drugu.
From the disk 28 there protrudes, from the part opposite the pin 27, a support element 29 to which there is hinged, by means of a first small pin 52, a lever 30, adapted to allow to impart the desired rotation to the second screw 24 on the part of the user. 
Od pločice 28, od dijela nasuprot klinu 27, strši nosivi element 29 na koji je pomoću prvog malog klina 52 obješena poluga 30, prilagođena tako da omogućuje prenošenje željene rotacije drugog vijka 24 na dio korisnika.
The method of claim 25, wherein therapeutically effective amount of crenolanib or a salt thereof is administered at least one of continuously, intermittently, systemically, or locally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove soli daje najmanje jednom kontinuirano, naizmjenično, sustavno 1li lokalno.
The method as claimed in claim 1, wherein the method further comprises applying wear resistant particles on the paper before the heating of the décor and the paper with the resin. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja čestica koje su otporne na habanje (16), poželjno čestice aluminij oksida na papir (2) prije zagrijavanja dekora (8).
reconstitution with Bacteriostatic Water for Injection or with 0.9% Sodium Chloride Injection. 
rekonstituciju s bakteriostatskom vodom za injektiranje ili s injekcijom 0,9% natrijevog klorida.
The method of claim 1 wherein the compound 1c is 3-fluoro-4-(6-hydroxyquinolin-2-yl)benzoic acid. 
Spoj ili sol prema zahtjevu 6, naznačen/a time, da spoj je 3-fluoro-4-(6-hidroksikinolin-2-il)benzoeva kiselina.
wherein the RNA is obtained by in vitro transcription or chemical synthesis. 
(ili) dopuštajući razvoj stanica koje imaju obilježja matičnih stanica, naznačen time da se RNA dobiva in vitro transkripcijom ili kemijskom sintezom.
laser producing a first image (19) in a first image area (18) without laser energy being transferred to the adjacent surface (13, 14); 
- lasersko produciranje prve slike (19) u prvom slikovnom području (18) bez transfera laserske energije na susjednu površinu (13, 14);